Chitosan as a Universal Drug Delivery Vehicle

Bose, Partha Pratim; Chatterjee, Urmimala

doi:10.1002/9781119143802.ch37

Cited by 1 publication

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Innovative treatments using combination NPs have emerged as a promising approach for improving the management of AD through intranasal delivery, which offers higher drug accumulation in the brain compared to equivalent drug solution formulations and systemic approaches [ 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ]. Among these approaches, derivatives of the chitosan (Cs) polymer, such as N , N , N -trimethyl chitosan (TMC), have garnered attention due to their positive biological features, including high mucosal absorption capacity, low toxicity, and ease of NP formation through ionic gelation [ 43 , 44 ]. In comparison to Cs, TMC exhibits excellent mucoadhesive properties and solubility in aqueous solutions across a wide pH range [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Synthesis of a Rivastigmine and Insulin Combinational Mucoadhesive Nanoparticle for Intranasal Delivery

Jamshidnejad-Tosaramandani,

Kashanian,

Karimi

et al. 2024

Polymers

View full text Add to dashboard Cite

Efficient drug delivery remains a critical challenge for treating neurodegenerative diseases, such as Alzheimer’s disease (AD). Using innovative nanomaterials, delivering current medications like acetylcholinesterase inhibitors to the brain through the intranasal route is a promising strategy for managing AD. Here, we developed a unique combinational drug delivery system based on N,N,N-trimethyl chitosan nanoparticles (NPs). These NPs encapsulate rivastigmine, the most potent acetylcholinesterase inhibitor, along with insulin, a complementary therapeutic agent. The spherical NPs exhibited a zeta potential of 17.6 mV, a size of 187.00 nm, and a polydispersity index (PDI) of 0.29. Our findings demonstrate significantly improved drug transport efficiency through sheep nasal mucosa using the NPs compared to drug solutions. The NPs exhibited transport efficiencies of 73.3% for rivastigmine and 96.9% for insulin, surpassing the efficiencies of the drug solutions, which showed transport efficiencies of 52% for rivastigmine and 21% for insulin ex vivo. These results highlight the potential of a new drug delivery system as a promising approach for enhancing nasal transport efficiency. These combinational mucoadhesive NPs offer a novel strategy for the simultaneous cerebral delivery of rivastigmine and insulin, which could prove helpful in developing effective treatments of AD and other neurodegenerative conditions.

show abstract